These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
67 related articles for article (PubMed ID: 9876576)
21. Study the effect of formulation variables on drug release from hydrophilic matrix tablets of milnacipran and prediction of in-vivo plasma profile. Singhvi G; Shah A; Yadav N; Saha RN Pharm Dev Technol; 2014 Sep; 19(6):708-16. PubMed ID: 23931031 [TBL] [Abstract][Full Text] [Related]
22. Microencapsulated Eudragit RS30D-coated controlled-release pellets: the influence of dissolution variables and topographical evaluation. Govender T; Dangor CM; Chetty DJ J Microencapsul; 1997; 14(1):1-13. PubMed ID: 8994071 [TBL] [Abstract][Full Text] [Related]
23. Developing dissolution testing methodologies for extended-release oral dosage forms with supersaturating properties. Case example: Solid dispersion matrix of indomethacin. Tajiri T; Morita S; Sakamoto R; Mimura H; Ozaki Y; Reppas C; Kitamura S Int J Pharm; 2015 Jul; 490(1-2):368-74. PubMed ID: 26022889 [TBL] [Abstract][Full Text] [Related]
24. Analysis of the enhanced oral bioavailability of fenofibrate lipid formulations in fasted humans using an in vitro-in silico-in vivo approach. Fei Y; Kostewicz ES; Sheu MT; Dressman JB Eur J Pharm Biopharm; 2013 Nov; 85(3 Pt B):1274-84. PubMed ID: 23500116 [TBL] [Abstract][Full Text] [Related]
25. Development of a predictive in vitro dissolution for clarithromycin granular suspension based on in vitro-in vivo correlations. Alkhalidi BA; Al-Ghazawi M; AlKhatib HS; Sallam A Pharm Dev Technol; 2010 Jun; 15(3):286-95. PubMed ID: 22716469 [TBL] [Abstract][Full Text] [Related]
26. Dissolution kinetics of bezafibrate in two solid forms for oral administration. Cadorniga R; Hernanez MT; Negro S; Burgos ML; Molina IT Eur J Drug Metab Pharmacokinet; 1991; Spec No 3():371-8. PubMed ID: 1820910 [TBL] [Abstract][Full Text] [Related]
27. In vitro dissolution of proton-pump inhibitor products intended for paediatric and geriatric use in physiological bicarbonate buffer. Liu F; Shokrollahi H Int J Pharm; 2015 May; 485(1-2):152-9. PubMed ID: 25746736 [TBL] [Abstract][Full Text] [Related]
28. A double-blind comparative multicentre study of controlled-release remoxipride, immediate-release remoxipride and haloperidol in schizophrenia. Hebenstreit GF; Laux G; Schubert H; Beckmann H; Amman J; Bunse J; Eikmeier G; Geretsegger C; Kanitz RD; Kanzow WT Pharmacopsychiatry; 1991 Sep; 24(5):153-8. PubMed ID: 1685572 [TBL] [Abstract][Full Text] [Related]
29. In vitro-in vivo correlations for three different commercial immediate-release indapamide tablets. Yaro P; He X; Liu W; Xun M; Ma Y; Li Z; Shi X Drug Dev Ind Pharm; 2014 Dec; 40(12):1670-6. PubMed ID: 24102615 [TBL] [Abstract][Full Text] [Related]
30. Setting dissolution specifications for modified-release dosage forms. Piscitelli DA; Young D Adv Exp Med Biol; 1997; 423():159-66. PubMed ID: 9269491 [TBL] [Abstract][Full Text] [Related]
31. Predictions of in vivo plasma concentrations from in vitro release kinetics: application to doxepin parenteral (i.m.) suspensions in lipophilic vehicles in dogs. Gido C; Langguth P; Mutschler E Pharm Res; 1994 Jun; 11(6):800-8. PubMed ID: 7937517 [TBL] [Abstract][Full Text] [Related]
32. Formulation development of sustained-release hydrophilic matrix tablets of zileuton. Qiu Y; Hui HW; Cheskin H Pharm Dev Technol; 1997 Aug; 2(3):197-204. PubMed ID: 9552447 [TBL] [Abstract][Full Text] [Related]
33. Influence of formulation composition and process on the characteristics and in vitro release from PLGA-based sustained release injectables. Meeus J; Scurr DJ; Appeltans B; Amssoms K; Annaert P; Davies MC; Roberts CJ; Van den Mooter G Eur J Pharm Biopharm; 2015 Feb; 90():22-9. PubMed ID: 25448071 [TBL] [Abstract][Full Text] [Related]
34. In vitro--in vivo correlation, a time scaling problem? Basic considerations on in vitro dissolution testing. Brockmeier D; von Hattingberg HM Arzneimittelforschung; 1982; 32(3):248-51. PubMed ID: 6896279 [TBL] [Abstract][Full Text] [Related]
35. Statistical optimization of indomethacin pellets coated with pH-dependent methacrylic polymers for possible colonic drug delivery. Akhgari A; Afrasiabi Garekani H; Sadeghi F; Azimaie M Int J Pharm; 2005 Nov; 305(1-2):22-30. PubMed ID: 16236475 [TBL] [Abstract][Full Text] [Related]
36. In-vitro dissolution methods for controlled release parenterals and their applicability to drug-eluting stent testing. Seidlitz A; Weitschies W J Pharm Pharmacol; 2012 Jul; 64(7):969-85. PubMed ID: 22686343 [TBL] [Abstract][Full Text] [Related]
37. Understanding the in vivo performance of enteric coated tablets using an in vitro-in silico-in vivo approach: case example diclofenac. Kambayashi A; Blume H; Dressman J Eur J Pharm Biopharm; 2013 Nov; 85(3 Pt B):1337-47. PubMed ID: 24056057 [TBL] [Abstract][Full Text] [Related]
38. Development and optimization of a multiple-unit controlled release formulation of a freely water soluble drug for once-daily administration. Shamma RN; Basalious EB; Shoukri RA Int J Pharm; 2011 Feb; 405(1-2):102-12. PubMed ID: 21145958 [TBL] [Abstract][Full Text] [Related]
39. Novel extended-release formulation of lovastatin by one-step melt granulation: in vitro and in vivo evaluation. Ochoa L; Igartua M; Hernández RM; Gascón AR; Solinis MA; Pedraz JL Eur J Pharm Biopharm; 2011 Feb; 77(2):306-12. PubMed ID: 21172434 [TBL] [Abstract][Full Text] [Related]
40. Dissolution testing of oral modified-release dosage forms. Garbacz G; Klein S J Pharm Pharmacol; 2012 Jul; 64(7):944-68. PubMed ID: 22686342 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]